Melana Yuzefpolskaya1, Bruno Bohn2, Paolo C Colombo1, Ryan T Demmer3,2, Azka Javaid1, Giulio M Mondellini1, Lorenzo Braghieri1, Alberto Pinsino1, Duygu Onat1, Barbara Cagliostro4, Andrea Kim1, Koji Takeda4, Yoshifumi Naka4, Maryjane Farr1, Gabriel T Sayer1, Nir Uriel1, Renu Nandakumar5, Sumit Mohan6,3. 1. Department of Medicine, Division of Cardiology (M.Y., A.J., G.M.M., L.B., A.P., D.O., A.K., M.F., G.T.S., N.U., P.C.C.), Columbia University Irving Medical Center, New York, NY. 2. Biomarkers Core Laboratory, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis (B.B., R.T.D.). 3. Department of Epidemiology, Mailman School of Public Health (S.M., R.T.D.), Columbia University Irving Medical Center, New York, NY. 4. Dpartment of Surgery, Division of Cardiac Surgery (B.C., K.T., Y.N.), Columbia University Irving Medical Center, New York, NY. 5. Biomarkers Core Laboratory, Irving Institute for Clinical and Translational Research (R.N.). 6. Department of Medicine, Division of Nephrology (S.M.), Columbia University Irving Medical Center, New York, NY.
Abstract
BACKGROUND: Trimethylamine N-oxide (TMAO)-a gut-derived metabolite-is elevated in heart failure (HF) and linked to poor prognosis. We investigated variations in TMAO in HF, left ventricular assist device (LVAD), and heart transplant (HT) and assessed its relation with inflammation, endotoxemia, oxidative stress, and gut dysbiosis. METHODS: We enrolled 341 patients. TMAO, CRP (C-reactive protein), IL (interleukin)-6, TNF-α (tumor necrosis factor alpha), ET-1 (endothelin-1), adiponectin, lipopolysaccharide, soluble CD14, and isoprostane were measured in 611 blood samples in HF (New York Heart Association class I-IV) and at multiple time points post-LVAD and post-HT. Gut microbiota were assessed via 16S rRNA sequencing among 327 stool samples. Multivariable regression models were used to assess the relationship between TMAO and (1) New York Heart Association class; (2) pre- versus post-LVAD or post-HT; (3) biomarkers of inflammation, endotoxemia, oxidative stress, and microbial diversity. RESULTS: ln-TMAO was lower among HF New York Heart Association class I (1.23 [95% CI, 0.52-1.94] µM) versus either class II, III, or IV (1.99 [95% CI, 1.68-2.30], 1.97 [95% CI, 1.71-2.24], and 2.09 [95% CI, 1.83-2.34] µM, respectively; all P<0.05). In comparison to class II-IV, ln-TMAO was lower 1 month post-LVAD (1.58 [95% CI, 1.32-1.83] µM) and 1 week and 1 month post-HT (0.97 [95% CI, 0.60-1.35] and 1.36 [95% CI, 1.01-1.70] µM). ln-TMAO levels in long-term LVAD (>6 months: 1.99 [95% CI, 1.76-2.22] µM) and HT (>6 months: 1.86 [95% CI, 1.66-2.05] µM) were not different from symptomatic HF. After multivariable adjustments, TMAO was not associated with biomarkers of inflammation, endotoxemia, oxidative stress, or microbial diversity. CONCLUSIONS: TMAO levels are increased in symptomatic HF patients and remain elevated long term after LVAD and HT. TMAO levels were independent from measures of inflammation, endotoxemia, oxidative stress, and gut dysbiosis.
BACKGROUND: Trimethylamine N-oxide (TMAO)-a gut-derived metabolite-is elevated in heart failure (HF) and linked to poor prognosis. We investigated variations in TMAO in HF, left ventricular assist device (LVAD), and heart transplant (HT) and assessed its relation with inflammation, endotoxemia, oxidative stress, and gut dysbiosis. METHODS: We enrolled 341 patients. TMAO, CRP (C-reactive protein), IL (interleukin)-6, TNF-α (tumor necrosis factor alpha), ET-1 (endothelin-1), adiponectin, lipopolysaccharide, soluble CD14, and isoprostane were measured in 611 blood samples in HF (New York Heart Association class I-IV) and at multiple time points post-LVAD and post-HT. Gut microbiota were assessed via 16S rRNA sequencing among 327 stool samples. Multivariable regression models were used to assess the relationship between TMAO and (1) New York Heart Association class; (2) pre- versus post-LVAD or post-HT; (3) biomarkers of inflammation, endotoxemia, oxidative stress, and microbial diversity. RESULTS: ln-TMAO was lower among HF New York Heart Association class I (1.23 [95% CI, 0.52-1.94] µM) versus either class II, III, or IV (1.99 [95% CI, 1.68-2.30], 1.97 [95% CI, 1.71-2.24], and 2.09 [95% CI, 1.83-2.34] µM, respectively; all P<0.05). In comparison to class II-IV, ln-TMAO was lower 1 month post-LVAD (1.58 [95% CI, 1.32-1.83] µM) and 1 week and 1 month post-HT (0.97 [95% CI, 0.60-1.35] and 1.36 [95% CI, 1.01-1.70] µM). ln-TMAO levels in long-term LVAD (>6 months: 1.99 [95% CI, 1.76-2.22] µM) and HT (>6 months: 1.86 [95% CI, 1.66-2.05] µM) were not different from symptomatic HF. After multivariable adjustments, TMAO was not associated with biomarkers of inflammation, endotoxemia, oxidative stress, or microbial diversity. CONCLUSIONS: TMAO levels are increased in symptomatic HF patients and remain elevated long term after LVAD and HT. TMAO levels were independent from measures of inflammation, endotoxemia, oxidative stress, and gut dysbiosis.
Authors: Albert Palleja; Kristian H Mikkelsen; Sofia K Forslund; Alireza Kashani; Kristine H Allin; Trine Nielsen; Tue H Hansen; Suisha Liang; Qiang Feng; Chenchen Zhang; Paul Theodor Pyl; Luis Pedro Coelho; Huanming Yang; Jian Wang; Athanasios Typas; Morten F Nielsen; Henrik Bjorn Nielsen; Peer Bork; Jun Wang; Tina Vilsbøll; Torben Hansen; Filip K Knop; Manimozhiyan Arumugam; Oluf Pedersen Journal: Nat Microbiol Date: 2018-10-22 Impact factor: 17.745
Authors: Martin Kummen; Cristiane C K Mayerhofer; Beate Vestad; Kaspar Broch; Ayodeji Awoyemi; Christopher Storm-Larsen; Thor Ueland; Arne Yndestad; Johannes R Hov; Marius Trøseid Journal: J Am Coll Cardiol Date: 2018-03-13 Impact factor: 24.094
Authors: Paul A Heidenreich; Nancy M Albert; Larry A Allen; David A Bluemke; Javed Butler; Gregg C Fonarow; John S Ikonomidis; Olga Khavjou; Marvin A Konstam; Thomas M Maddox; Graham Nichol; Michael Pham; Ileana L Piña; Justin G Trogdon Journal: Circ Heart Fail Date: 2013-04-24 Impact factor: 8.790
Authors: Zeneng Wang; W H Wilson Tang; Jennifer A Buffa; Xiaoming Fu; Earl B Britt; Robert A Koeth; Bruce S Levison; Yiying Fan; Yuping Wu; Stanley L Hazen Journal: Eur Heart J Date: 2014-02-03 Impact factor: 29.983
Authors: Toru Suzuki; Yoshiyuki Yazaki; Adriaan A Voors; Donald J L Jones; Daniel C S Chan; Stefan D Anker; John G Cleland; Kenneth Dickstein; Gerasimos Filippatos; Hans L Hillege; Chim C Lang; Piotr Ponikowski; Nilesh J Samani; Dirk J van Veldhuisen; Faiez Zannad; Aeilko H Zwinderman; Marco Metra; Leong L Ng Journal: Eur J Heart Fail Date: 2018-10-29 Impact factor: 15.534
Authors: Anja Sandek; Juergen Bauditz; Alexander Swidsinski; Sabine Buhner; Jutta Weber-Eibel; Stephan von Haehling; Wieland Schroedl; Tim Karhausen; Wolfram Doehner; Mathias Rauchhaus; Philip Poole-Wilson; Hans-Dieter Volk; Herbert Lochs; Stefan D Anker Journal: J Am Coll Cardiol Date: 2007-10-01 Impact factor: 24.094
Authors: Katie A Meyer; Thomas Z Benton; Brian J Bennett; David R Jacobs; Donald M Lloyd-Jones; Myron D Gross; J Jeffrey Carr; Penny Gordon-Larsen; Steven H Zeisel Journal: J Am Heart Assoc Date: 2016-10-21 Impact factor: 5.501